Fundraising Fox
Spero
Cambridge, US · 3 known investors
Find your way into Spero
Sign up to see every warm intro you have to Spero
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Spero team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Spero Therapeutics is a clinical-stage biopharmaceutical company developing next-generation immunology and inflammation medicines, particularly targeting patients with serious diseases and major treatment gaps. The company's lead program, SP001, is a novel anti-CD40L monoclonal antibody being advanced in IgG4-related disease and other immune-related conditions.
Investors · 3
Atlas VenturereportedCambridge · $500K – $1M
How we know: funding news · Not right? Tell us
The Kraft GroupreportedFoxborough
How we know: funding news · Not right? Tell us
In the news
Frequently asked questions
- What does Spero do?
- Spero Therapeutics is a clinical-stage biopharmaceutical company developing next-generation immunology and inflammation medicines, particularly targeting patients with serious diseases and major treatment gaps. The company's lead program, SP001, is a novel anti-CD40L monoclonal antibody being advanced in IgG4-related disease and other immune-related conditions.
- Who are Spero's investors?
- Spero's investors include HEALTHCARE ROYALTY PARTNERS, Atlas Venture, The Kraft Group.
- Where is Spero headquartered?
- Spero is headquartered in Cambridge, US.